Abstract: The present invention relates to cocrystalline forms of 4-[4-[3- chloro-4-[l-(5-fluoro-2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[l,5- a]pyridin-6-yl]-5-methyl-triazol-l-yl]piperidine-l-carbonitrile, R- enantiomer ("Isomer 2"), with gallic acid (I), and to cocrystalline forms of 4-[4-[3-chloro-4-[l-(2-pyridyl)-2- hydroxy-ethoxy]pyrazolo[l,5-a]pyridin-6-yl]-5-methyl-triazol-l- yl]piperidine-l-carbonitrile, R-enantiomer ("Isomer A"), with gallic acid or nicotine amide (II) The compounds are fibroblast growth factor receptor 3 (FGFR3) inhibitors for use in methods of treatment of e.g. cancer. Provided herein are also methods for the preparation of said cocrystalline forms.
| # | Name | Date |
|---|---|---|
| 1 | 202517027596-STATEMENT OF UNDERTAKING (FORM 3) [25-03-2025(online)].pdf | 2025-03-25 |
| 2 | 202517027596-PRIORITY DOCUMENTS [25-03-2025(online)].pdf | 2025-03-25 |
| 3 | 202517027596-POWER OF AUTHORITY [25-03-2025(online)].pdf | 2025-03-25 |
| 4 | 202517027596-MARKED COPIES OF AMENDEMENTS [25-03-2025(online)].pdf | 2025-03-25 |
| 5 | 202517027596-FORM 18 [25-03-2025(online)].pdf | 2025-03-25 |
| 6 | 202517027596-FORM 13 [25-03-2025(online)].pdf | 2025-03-25 |
| 7 | 202517027596-FORM 1 [25-03-2025(online)].pdf | 2025-03-25 |
| 8 | 202517027596-DECLARATION OF INVENTORSHIP (FORM 5) [25-03-2025(online)].pdf | 2025-03-25 |
| 9 | 202517027596-COMPLETE SPECIFICATION [25-03-2025(online)].pdf | 2025-03-25 |
| 10 | 202517027596-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [25-03-2025(online)].pdf | 2025-03-25 |
| 11 | 202517027596-AMMENDED DOCUMENTS [25-03-2025(online)].pdf | 2025-03-25 |
| 12 | 202517027596-Proof of Right [14-05-2025(online)].pdf | 2025-05-14 |
| 13 | 202517027596-FORM 3 [14-05-2025(online)].pdf | 2025-05-14 |